A writer for life with an enduring love for anime, manga, video games, and other entertainment delights that offer an adventure-filled escape into a new world. Watching anime and reading manga since ...

Abstract: Accurate three-dimensional (3-D) position and velocity estimates of an aircraft are important for air traffic control (ATC) systems. An ATC 2-D radar measures the slant range and azimuth of ...

When Google unveiled TurboQuant, an AI data compression technology that promises to slash the amount of memory required to serve models, many hoped it would help with a memory shortage that has seen ...

In his column “Acrademics,” Alexandre Acra ’26 sheds light on the ins and outs of Stanford and Silicon Valley culture. Dear Acrademics, The world around us seems to be losing rigor and specificity by ...

IND application for Descartes-08 in myositis accepted by FDA; seamless adaptive clinical trial offering potential opportunity for a single pivotal trial expected to commence in 1H26 Phase 1/2 ...

As part of the redesign of the Vector Addition simulation, we are introducing a new vector labeling system specifically for the Lab screen. This screen differs from others in that users can create up ...

Cartesian Therapeutics, Inc. has announced the enrollment of the first participant in its Phase 3 AURORA trial for Descartes-08, its lead cell therapy candidate aimed at treating myasthenia gravis (MG ...

NEW YORK--(BUSINESS WIRE)--Cartesian Growth Corporation III (the “Company”) announced today the closing of its initial public offering of 27,600,000 units, including 3,600,000 units pursuant to the ...

Phase 3 trial of Descartes-08 in myasthenia gravis to start in 1H25 Cartesian Therapeutics has secured an agreement from the US Food and Drug Administration (FDA) under the Special Protocol Assessment ...

Abstract: A new hybrid method CBFM/AIM-EDM is introduced to analyze the bistatic radar cross section (BCS) of perfect electrical conductor (PEC) scatterers. This method efficiently treats ...

Cartesian Therapeutics shared plans to raise $130 million. (Hakinmhan/iStock/Getty Images Plus) Cartesian Therapeutics has claimed a phase 2b win for its BCMA-directed CAR-T therapy in generalized ...